Ketamine
Also known as: Esketamine, Spravato, Special K, Vitamin K
Ketamine is a dissociative anesthetic that blocks NMDA receptors in the brain, which affects glutamate signaling and may help rebuild connections between nerve cells weakened by chronic stress and depression. Unlike classic psychedelics, it does not work mainly through serotonin receptors, and it ca...
Applications
5
Clinical Trials
3
Evidence Tier
strong
Duration
IV effects last 45-60 minutes; antidepressant effects may last days to weeks; some people need repeat treatments
Overview
Ketamine is a dissociative anesthetic that blocks NMDA receptors in the brain, which affects glutamate signaling and may help rebuild connections between nerve cells weakened by chronic stress and depression. Unlike classic psychedelics, it does not work mainly through serotonin receptors, and it can act within hours rather than weeks. Esketamine (Spravato), a nasal spray made from one form of ketamine, was FDA-approved in 2019 for treatment-resistant depression alongside an oral antidepressant, and in January 2025 as a treatment on its own; in the monotherapy trial, 22.5% of people on esketamine reached remission at four weeks versus 7.6% on placebo. Esketamine is given only in certified clinics, with monitoring after each dose. Racemic ketamine is not FDA-approved for any psychiatric condition; clinics that give IV ketamine for depression use it off-label. In October 2023, FDA warned about compounded ketamine for psychiatric use, including oral forms prescribed by telehealth for use at home, because no one monitors patients during treatment. During a supervised treatment, ketamine causes dissociation, altered time perception and dreamlike states that usually fade within an hour or two.
Traditional Use
No traditional use; ketamine was synthesized in 1962 as a safer alternative to PCP anesthetic. Used in emergency and veterinary medicine since 1970.
Therapeutic Applications
Clinical Trials
Esketamine (Spravato) Monotherapy for TRD
Completed - FDA Approved January 2025Esketamine for Depression with Suicidal Thoughts (ASPIRE I and II)
Completed - FDA Approved 2020Ketamine for PTSD with Prolonged Exposure
OngoingRisks & Contraindications
Potential Risks
- •Dissociation and altered perception during treatment
- •Transient increases in blood pressure
- •Sedation and dizziness
- •Nausea and vomiting
- •Potential for abuse and psychological dependence
- •Bladder toxicity with chronic high-dose use
- •Esketamine requires at least 2 hours of monitoring after each treatment under its FDA safety program (REMS)
Contraindications
- Aneurysmal vascular disease
- Arteriovenous malformation
- History of intracerebral hemorrhage
- Uncontrolled hypertension
- Active substance use disorder
- Pregnancy (unless benefits outweigh risks)
Safety screening
Psychedelics are not safe for everyone. Talk with a licensed clinician first, especially if any of these apply to you:
- Antidepressants such as SSRIs and SNRIs, and other medicines that raise serotonin (tramadol, for example): they can blunt the effect of psychedelics, and with some substances, such as MDMA and ayahuasca, raise the risk of serotonin syndrome.
- Lithium: seizures have been reported when lithium is combined with classic psychedelics such as psilocybin and LSD.
- MAOIs, including the MAOIs in ayahuasca: dangerous interactions with many medicines, other substances and some foods.
- Heart disease, high blood pressure, or a heart rhythm problem such as long QT syndrome.
- A personal or family history of psychosis, schizophrenia or bipolar disorder.
- Pregnancy or breastfeeding.
Never stop or change a prescribed medicine without your prescriber.
Gabriel doesn't give psychedelic dosing and doesn't help anyone obtain psychedelics. This page explains research and risks; it is not medical advice.
If you're in crisis, call or text 988 (Suicide and Crisis Lifeline). For a medical emergency, call 911.
Legal Status
Legal status as of October 2026. Laws change; check the current law where you live. This is not legal advice.
United States
Esketamine (Spravato) is FDA-approved for treatment-resistant depression and for depression with suicidal thoughts or actions, and is given only in certified clinics under an FDA safety program (REMS). Racemic ketamine is Schedule III and FDA-approved only as an anesthetic; IV use for depression is off-label.
International
Approved as an anesthetic in many countries. Esketamine is approved for depression in the EU and Canada. Controlled substance in most countries.
Key Researchers
Key Studies
- 1Zarate et al. - A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression (2006)
- 2Daly et al. - Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression (2018)
- 3Wilkinson et al. - The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation (2018)
Quick Facts
Questions? Ask Gabriel
Gabriel can help you find and book licensed clinicians who offer ketamine or esketamine treatment. Gabriel doesn't prescribe ketamine.
Ask Gabriel